VA
CRBP icon

Verdad Advisers’s Corbus Pharmaceuticals CRBP Stock Holding History

Verdad Advisers’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$597K Buy
63,603
+13,351
+27% +$126K 0.57% 65
2026
Q1 		$472K Buy
+50,252
New +$423K 0.53% 67

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Verdad Advisers's CRBP Position: Q2 2026 in Review

Verdad Advisers increased its Corbus Pharmaceuticals (CRBP) stake by 27% in Q2 2026, buying an estimated $126K and bringing the position to 63,603 shares worth $597K. The position accounts for 0.57% of the portfolio, ranked #65.

Verdad Advisers first reported a position in CRBP in Q1 2026 and has held it in 2 quarters since. 107 funds tracked by Wall St. Rank hold CRBP as of Q2 2026.

  • Verdad Advisers held 63,603 shares of Corbus Pharmaceuticals worth $597K as of Q2 2026.
  • Verdad Advisers bought 13,351 Corbus Pharmaceuticals shares in Q2 2026, an estimated $126K.
  • Corbus Pharmaceuticals made up 0.57% of Verdad Advisers's portfolio in Q2 2026, its #65 holding.
  • Verdad Advisers first reported a position in Corbus Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q2 2026.

Based on Verdad Advisers's 13F filing for Q2 2026, filed 14 Aug 2026.